Inhaled mycophenolate mofetil formulations for the prevention of lung allograft rejection
The use of lung transplantation, a life saving intervention, has been increasing over the last thirty years with a disappointing median survival of only 4.8 years. Despite the progress made in immunosuppressive therapies, allograft rejection following transplantation is the leading cause of death. A...
Main Author: | Dugas, Helene Laurence |
---|---|
Format: | Others |
Language: | English |
Published: |
2012
|
Subjects: | |
Online Access: | http://hdl.handle.net/2152/ETD-UT-2012-08-5903 |
Similar Items
-
Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?: A mini-review
by: Alice Tung Wan Song, et al. -
Duodenal villous atrophy caused by Mycophenolate Mofetil in patients with solid organ transplantation: case report
by: Giuston Mendoza-Chuctaya, et al.
Published: (2016-03-01) -
Acute pancreatitis induced by mycophenolate mofetil in a kidney transplant patient
by: Einollahi Behzad, et al.
Published: (2015-04-01) -
Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients
by: Jun Zhang, et al.
Published: (2018-08-01) -
Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
by: Seung Woon Park, et al.
Published: (2016-06-01)